PBA
OLMA icon

Paradigm Biocapital Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

Paradigm Biocapital Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$120M Buy
8,020,576
+476,404
+6% +$10.6M 2.44% 12
2025
Q4 		$189M Buy
7,544,172
+750,000
+11% +$13.3M 4.81% 7
2025
Q3 		$66.5M Buy
6,794,172
+30,000
+0.4% +$180K 1.89% 17
2025
Q2 		$28.8M Buy
6,764,172
+23,000
+0.3% +$103K 1.23% 22
2025
Q1 		$25.3M Sell
6,741,172
-563,798
-8% -$2.84M 1.16% 21
2024
Q4 		$42.6M Buy
7,304,970
+1,801,370
+33% +$18M 1.48% 16
2024
Q3 		$65.7M Sell
5,503,600
-2,400,000
-30% -$30.7M 2.22% 15
2024
Q2 		$85.5M Hold
7,903,600
– – 3.27% 12
2024
Q1 		$89.5M Hold
7,903,600
– – 3.15% 14
2023
Q4 		$111M Buy
7,903,600
+100,000
+1% +$1.34M 5.19% 6
2023
Q3 		$96.4M Buy
7,803,600
+4,072,554
+109% +$41.5M 6.54% 4
2023
Q2 		$33.7M Buy
3,731,046
+1,348,669
+57% +$8.14M 2.6% 17
2023
Q1 		$8.27M Buy
+2,382,377
New +$9.72M 0.78% 24

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Paradigm Biocapital Advisors's OLMA Position: Q1 2026 in Review

Paradigm Biocapital Advisors increased its Olema Pharmaceuticals (OLMA) stake by 6.3% in Q1 2026, buying an estimated $10.6M and bringing the position to 8,020,576 shares worth $120M. The position accounts for 2.44% of the portfolio, ranked #12.

Paradigm Biocapital Advisors first reported a position in OLMA in Q1 2023 and has held it in 13 quarters since. The position peaked at $189M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Paradigm Biocapital Advisors held 8,020,576 shares of Olema Pharmaceuticals worth $120M as of Q1 2026.
  • Paradigm Biocapital Advisors bought 476,404 Olema Pharmaceuticals shares in Q1 2026, an estimated $10.6M.
  • Olema Pharmaceuticals made up 2.44% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #12 holding.
  • Paradigm Biocapital Advisors first reported a position in Olema Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Paradigm Biocapital Advisors's Olema Pharmaceuticals position peaked at $189M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.